Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
The company’s shares traded at R102 in May 2018, and they dropped to R55 in May 2019, well before the pandemic hit the world. In May 2017 the share traded at R136 and it was above R200 in 2016.
Before rejecting this offer the Mediclinic board should take a good look at itself. They may just find that the decision to invest in Britain was a poor one. At the current price of R86 the share carries a price to earnings ratio of 22.3, which is above its two major competitors.
Shareholders should be happy with an offer that adds 9% to their current value.
Chris Richards Craighall Park
JOIN THE DISCUSSION: Send us an email with your comments to letters@businesslive.co.za. Letters of more than 300 words will be edited for length. Anonymous correspondence will not be published. Writers should include a daytime telephone number.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
LETTER: Mediclinic offer adds to value
You choose to criticise the offer being made for Mediclinic’s shares, which you describe as a penny-pinching (“Mediclinic board is right to reject Remgro’s R38bn takeover bid”, June 15).
The company’s shares traded at R102 in May 2018, and they dropped to R55 in May 2019, well before the pandemic hit the world. In May 2017 the share traded at R136 and it was above R200 in 2016.
Before rejecting this offer the Mediclinic board should take a good look at itself. They may just find that the decision to invest in Britain was a poor one. At the current price of R86 the share carries a price to earnings ratio of 22.3, which is above its two major competitors.
Shareholders should be happy with an offer that adds 9% to their current value.
Chris Richards
Craighall Park
JOIN THE DISCUSSION: Send us an email with your comments to letters@businesslive.co.za. Letters of more than 300 words will be edited for length. Anonymous correspondence will not be published. Writers should include a daytime telephone number.
EDITORIAL: Mediclinic board is right to reject Remgro’s R38bn takeover bid
Mediclinic shares jump as market anticipates fatter takeover offer
Netcare and rivals’ profits up but still not at 2020 levels
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Remgro looking for equal partnership in possible Mediclinic buyout
Remgro’s Mediclinic blunder
WATCH: Technical analysis of Sabvest, Alibaba, JD.com and Mediclinic
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.